![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 15, 2021 8:43:34 AM
ae kusterer Wednesday, 09/15/21 08:36:45 AM
Re: None 0
Post #
402167
of 402172
Linda Liau speaks 10/17 at 12/45 p.m. at CNS. Is she booked for any other presentations in September, October, or Novemebr, '21?
https://2021meeting.cns.org/Assets/edccc356-3f88-4c09-ba3f-b101e0a28585/637636915731000000/cns21787-21am-prelim-05242021-copy-with-4-new-gss-pages-080421-3-pm-pdf?inline=ture
NEW! 12:45–4:15 pm
SYM20B: Immunotherapy for Brain Tumors: New
Concepts
Course Directors: E. Antonio Chiocca, Linda M. Liau
Faculty: Nduka M. Amankulor, William T. Curry, Peter E.
Fecci, Amy B. Heimberger, Michael Lim, Edjah K. Nduom,
Hideho Okada, Ian F. Parney
Course Description: This symposium will provide a brief
overview of relevant immunological principles and define
discrete immune pathways regulating the initiation and
progression of malignant brain tumors. More importantly,
cutting-edge immunotherapeutic approaches for the
treatment of CNS tumors will be defined.
Learning Objectives:
? Evaluate various immune pathways that contribute to the
formation and progression of CNS malignancies
? Compare different immunotherapeutic strategies,
including virotherapy, adoptive cellular immunotherapy,
and immune checkpoint inhibition
? Compare neoadjuvant and adjuvant immunotherapy
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM